ASSOCIATION OF DIABETES MELLITUS TYPE 2 AND ANTIDIABETIC DRUGS WITH PANCREATIC CARCINOMA: A LITERATURE REVIEW

Detalhes bibliográficos
Autor(a) principal: do Monte, Larissa Emilly Fiusa
Data de Publicação: 2021
Outros Autores: Carneiro, Juliana Ramos, Mendes Filho, Antonio Camilo Correia, dos Santos, Leonardo Silva, Veloso, Marcus Vinicius Lindoso Silva, Leal, Plinio da Cunha
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: Revista Uningá (Online)
Texto Completo: https://revista.uninga.br/uninga/article/view/3944
Resumo: Pancreatic cancer has a high mortality rate and its diagnosis has often been associated with that of type 2 diabetes mellitus (DMT2), although the pathophysiological mechanisms of this relationship still require clarification. Thus, the aim of this study is to analyze aspects of the association between DMT2 and its pharmacological therapy with the development of pancreatic carcinoma. To this purpose, a thorough search of the literature published between 2015 and 2020 in electronic health databases was carried out, and, after the selection process, 13 articles on BHS and 14 on PUBMED were included in this study. In summary, the inflammatory characteristic of DMT2, hyperinsulinemia and insulin resistance are pathophysiological hypotheses of the association. Furthermore, the relationship between long-term diabetes and the development of carcinoma is significant, although recent onset diabetes is also demonstrated to be relevant. In addition, the association between antidiabetic drugs and pancreatic cancer is assessed. In this regard, some drugs, such as metformin, are associated with antitumor effects. In contrast, incretins are related to carcinogenesis, due to their potential deleterious effects on the pancreas. In parallel, insulin can amplify the relationship between hyperinsulinemia and the risk of malignancy, as well as drugs such as sulfonylureas, which are associated with an increased risk of cancer for causing abnormal stimulation of cell proliferation.
id UNINGA-1_dee5f4ac1e64bcdc15dd69fe1a56278c
oai_identifier_str oai:ojs.revista.uninga.br:article/3944
network_acronym_str UNINGA-1
network_name_str Revista Uningá (Online)
repository_id_str
spelling ASSOCIATION OF DIABETES MELLITUS TYPE 2 AND ANTIDIABETIC DRUGS WITH PANCREATIC CARCINOMA: A LITERATURE REVIEWASSOCIAÇÃO DA DIABETES MELLITUS TIPO 2 E DOS FÁRMACOS ANTIDIABÉTICOS COM O CÂNCER PANCREÁTICO: UMA REVISÃO DE LITERATURAAdultoCâncer de pâncreasDiabete Mellitus tipo 2Carcinoma pancreáticoDiabetes MellitusAdultDiabetes mellitus type 2Pancreatic neoplasmsPancreatic carcinomaDiabetesPancreatic cancer has a high mortality rate and its diagnosis has often been associated with that of type 2 diabetes mellitus (DMT2), although the pathophysiological mechanisms of this relationship still require clarification. Thus, the aim of this study is to analyze aspects of the association between DMT2 and its pharmacological therapy with the development of pancreatic carcinoma. To this purpose, a thorough search of the literature published between 2015 and 2020 in electronic health databases was carried out, and, after the selection process, 13 articles on BHS and 14 on PUBMED were included in this study. In summary, the inflammatory characteristic of DMT2, hyperinsulinemia and insulin resistance are pathophysiological hypotheses of the association. Furthermore, the relationship between long-term diabetes and the development of carcinoma is significant, although recent onset diabetes is also demonstrated to be relevant. In addition, the association between antidiabetic drugs and pancreatic cancer is assessed. In this regard, some drugs, such as metformin, are associated with antitumor effects. In contrast, incretins are related to carcinogenesis, due to their potential deleterious effects on the pancreas. In parallel, insulin can amplify the relationship between hyperinsulinemia and the risk of malignancy, as well as drugs such as sulfonylureas, which are associated with an increased risk of cancer for causing abnormal stimulation of cell proliferation.O câncer de pâncreas possui alta taxa de mortalidade e, com frequência, seu diagnóstico tem sido associado ao de diabetes mellitus tipo 2 (DMT2), embora os mecanismos fisiopatológicos dessa relação ainda necessitem de esclarecimentos. Dessa forma, o objetivo deste estudo é analisar os aspectos da associação entre a DMT2 e sua terapia farmacológica com o desenvolvimento de carcinoma pancreático. Para este fim, realizou-se uma busca criteriosa da literatura publicada entre 2015 e 2020 em bases de dados eletrônicas em saúde, e, após o processo de seleção, 13 artigos na BVS e 14 na PUBMED foram incluídos neste estudo. Em suma, a característica inflamatória da DMT2, a hiperinsulinemia e a resistência à insulina são hipóteses fisiopatológicas da associação. Outrossim, é significativa a relação da diabetes de longa duração com o desenvolvimento do carcinoma, apesar de a diabetes de início recente também demonstrar-se relevante. Ademais, a associação entre medicamentos antidiabéticos e câncer de pâncreas também é avaliada. Sob esse viés, alguns medicamentos, como a metformina, estão associados a efeitos antitumorais. Em contrapartida, as incretinas estão relacionadas à carcinogênese, devido aos seus potenciais efeitos deletérios no pâncreas. Em paralelo, a insulina pode amplificar a relação entre hiperinsulinemia e o risco de malignidade, assim como drogas como as sulfonilureias, que estão associadas ao risco aumentado de câncer por provocar estimulação anormal da proliferação celular.Editora Uningá2021-09-24info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionTEXTOapplication/pdfapplication/pdfhttps://revista.uninga.br/uninga/article/view/394410.46311/2318-0579.58.eUJ3944Revista Uningá; Vol. 58 (2021); eUJ3944Revista Uningá; v. 58 (2021); eUJ39442318-057910.46311/ru.v58i0reponame:Revista Uningá (Online)instname:Centro Universitário Uningáinstacron:UNINGAporenghttps://revista.uninga.br/uninga/article/view/3944/2413https://revista.uninga.br/uninga/article/view/3944/241410.46311/ru.v58i0.3944.g241310.46311/ru.v58i0.3944.g2414Copyright (c) 2021 UNINGÁ JOURNALinfo:eu-repo/semantics/openAccessdo Monte, Larissa Emilly FiusaCarneiro, Juliana RamosMendes Filho, Antonio Camilo Correiados Santos, Leonardo SilvaVeloso, Marcus Vinicius Lindoso SilvaLeal, Plinio da Cunha2023-10-20T18:43:58Zoai:ojs.revista.uninga.br:article/3944Revistahttps://revista.uninga.br/uninga/indexPUBhttps://revista.uninga.br/uninga/oairevistauninga@uninga.edu.br2318-05792318-0579opendoar:2023-10-20T18:43:58Revista Uningá (Online) - Centro Universitário Uningáfalse
dc.title.none.fl_str_mv ASSOCIATION OF DIABETES MELLITUS TYPE 2 AND ANTIDIABETIC DRUGS WITH PANCREATIC CARCINOMA: A LITERATURE REVIEW
ASSOCIAÇÃO DA DIABETES MELLITUS TIPO 2 E DOS FÁRMACOS ANTIDIABÉTICOS COM O CÂNCER PANCREÁTICO: UMA REVISÃO DE LITERATURA
title ASSOCIATION OF DIABETES MELLITUS TYPE 2 AND ANTIDIABETIC DRUGS WITH PANCREATIC CARCINOMA: A LITERATURE REVIEW
spellingShingle ASSOCIATION OF DIABETES MELLITUS TYPE 2 AND ANTIDIABETIC DRUGS WITH PANCREATIC CARCINOMA: A LITERATURE REVIEW
do Monte, Larissa Emilly Fiusa
Adulto
Câncer de pâncreas
Diabete Mellitus tipo 2
Carcinoma pancreático
Diabetes Mellitus
Adult
Diabetes mellitus type 2
Pancreatic neoplasms
Pancreatic carcinoma
Diabetes
title_short ASSOCIATION OF DIABETES MELLITUS TYPE 2 AND ANTIDIABETIC DRUGS WITH PANCREATIC CARCINOMA: A LITERATURE REVIEW
title_full ASSOCIATION OF DIABETES MELLITUS TYPE 2 AND ANTIDIABETIC DRUGS WITH PANCREATIC CARCINOMA: A LITERATURE REVIEW
title_fullStr ASSOCIATION OF DIABETES MELLITUS TYPE 2 AND ANTIDIABETIC DRUGS WITH PANCREATIC CARCINOMA: A LITERATURE REVIEW
title_full_unstemmed ASSOCIATION OF DIABETES MELLITUS TYPE 2 AND ANTIDIABETIC DRUGS WITH PANCREATIC CARCINOMA: A LITERATURE REVIEW
title_sort ASSOCIATION OF DIABETES MELLITUS TYPE 2 AND ANTIDIABETIC DRUGS WITH PANCREATIC CARCINOMA: A LITERATURE REVIEW
author do Monte, Larissa Emilly Fiusa
author_facet do Monte, Larissa Emilly Fiusa
Carneiro, Juliana Ramos
Mendes Filho, Antonio Camilo Correia
dos Santos, Leonardo Silva
Veloso, Marcus Vinicius Lindoso Silva
Leal, Plinio da Cunha
author_role author
author2 Carneiro, Juliana Ramos
Mendes Filho, Antonio Camilo Correia
dos Santos, Leonardo Silva
Veloso, Marcus Vinicius Lindoso Silva
Leal, Plinio da Cunha
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv do Monte, Larissa Emilly Fiusa
Carneiro, Juliana Ramos
Mendes Filho, Antonio Camilo Correia
dos Santos, Leonardo Silva
Veloso, Marcus Vinicius Lindoso Silva
Leal, Plinio da Cunha
dc.subject.por.fl_str_mv Adulto
Câncer de pâncreas
Diabete Mellitus tipo 2
Carcinoma pancreático
Diabetes Mellitus
Adult
Diabetes mellitus type 2
Pancreatic neoplasms
Pancreatic carcinoma
Diabetes
topic Adulto
Câncer de pâncreas
Diabete Mellitus tipo 2
Carcinoma pancreático
Diabetes Mellitus
Adult
Diabetes mellitus type 2
Pancreatic neoplasms
Pancreatic carcinoma
Diabetes
description Pancreatic cancer has a high mortality rate and its diagnosis has often been associated with that of type 2 diabetes mellitus (DMT2), although the pathophysiological mechanisms of this relationship still require clarification. Thus, the aim of this study is to analyze aspects of the association between DMT2 and its pharmacological therapy with the development of pancreatic carcinoma. To this purpose, a thorough search of the literature published between 2015 and 2020 in electronic health databases was carried out, and, after the selection process, 13 articles on BHS and 14 on PUBMED were included in this study. In summary, the inflammatory characteristic of DMT2, hyperinsulinemia and insulin resistance are pathophysiological hypotheses of the association. Furthermore, the relationship between long-term diabetes and the development of carcinoma is significant, although recent onset diabetes is also demonstrated to be relevant. In addition, the association between antidiabetic drugs and pancreatic cancer is assessed. In this regard, some drugs, such as metformin, are associated with antitumor effects. In contrast, incretins are related to carcinogenesis, due to their potential deleterious effects on the pancreas. In parallel, insulin can amplify the relationship between hyperinsulinemia and the risk of malignancy, as well as drugs such as sulfonylureas, which are associated with an increased risk of cancer for causing abnormal stimulation of cell proliferation.
publishDate 2021
dc.date.none.fl_str_mv 2021-09-24
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
TEXTO
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://revista.uninga.br/uninga/article/view/3944
10.46311/2318-0579.58.eUJ3944
url https://revista.uninga.br/uninga/article/view/3944
identifier_str_mv 10.46311/2318-0579.58.eUJ3944
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://revista.uninga.br/uninga/article/view/3944/2413
https://revista.uninga.br/uninga/article/view/3944/2414
10.46311/ru.v58i0.3944.g2413
10.46311/ru.v58i0.3944.g2414
dc.rights.driver.fl_str_mv Copyright (c) 2021 UNINGÁ JOURNAL
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 UNINGÁ JOURNAL
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Editora Uningá
publisher.none.fl_str_mv Editora Uningá
dc.source.none.fl_str_mv Revista Uningá; Vol. 58 (2021); eUJ3944
Revista Uningá; v. 58 (2021); eUJ3944
2318-0579
10.46311/ru.v58i0
reponame:Revista Uningá (Online)
instname:Centro Universitário Uningá
instacron:UNINGA
instname_str Centro Universitário Uningá
instacron_str UNINGA
institution UNINGA
reponame_str Revista Uningá (Online)
collection Revista Uningá (Online)
repository.name.fl_str_mv Revista Uningá (Online) - Centro Universitário Uningá
repository.mail.fl_str_mv revistauninga@uninga.edu.br
_version_ 1797042158805450752